ArticleJournal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing2025
A randomized controlled trial of two pulsed field ablation systems for paroxysmal atrial fibrillation: the DUAL-PULSE trial rationale and design.
Article in Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe energy source for atrial fibrillation (AF) catheter ablation is shifting from thermal energy to pulsed field ablation (PFA), introducing several systems with distinct pulse settings and catheter designs. This study aims to compare the efficacy and safety of two PFA systems: the PulseSelect™ and FARAPULSE™ PFA systems.
methodsThe DUAL-PULSE trial is a multicenter, prospective, open-label, randomized controlled trial conducted at eight centers across Japan (UMIN000056534). A total of 180 patients undergoing an index ablation for paroxysmal AF will be enrolled. They will be randomly assigned in a 1:1 ratio to either the PulseSelect™ or FARAPULSE™ group using permuted block randomization. The study was approved by the Institutional Review Boards at all centers.
resultsThe primary endpoint is the one-year atrial arrhythmia recurrence-free rate, defined as the proportion of patients remaining free from any atrial arrhythmia lasting ≥ 30 s without antiarrhythmic drug use after a 90-day blanking period. Secondary endpoints include the one-year procedure-related adverse event rate, defined as the proportion of patients experiencing any procedure-related complications, biomarkers of myocardial injury, PFA-related hemolysis, and changes in the sinus rate during a one-year follow-up. The silent cerebral ischemic event rate in patients undergoing brain magnetic resonance imaging post-procedure will be evaluated as an exploratory endpoint.
conclusionThe DUAL-PULSE trial is a multicenter, prospective, open-label, randomized controlled trial that will directly compare the efficacy and safety of the two PFA systems. This study will provide a better understanding of the advantages and limitations of each system.
Indexed as
Identifiers
41042294What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.